| Literature DB >> 25568440 |
Janjira Thaipadungpanit1, Premjit Amornchai2, Emma K Nickerson3, Gumphol Wongsuvan2, Vanaporn Wuthiekanun2, Direk Limmathurotsakul4, Sharon J Peacock5.
Abstract
Molecular typing of 246 Staphylococcus aureus isolates from unselected patients in Thailand showed that 10 (4.1%) were actually Staphylococcus argenteus. Contrary to the suggestion that S. argenteus is less virulent than S. aureus, we demonstrated comparable rates of morbidity, death, and health care-associated infection in patients infected with either of these two species.Entities:
Mesh:
Year: 2015 PMID: 25568440 PMCID: PMC4390622 DOI: 10.1128/JCM.03049-14
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 5.948
FIG 1Phylogenetic tree of 246 putative S. aureus isolates based on concatenated sequences of 7 MLST loci using the maximum-likelihood method. Blue dots represent STs identified for the 246 study isolates, and black dots represent 38 STs downloaded from the MLST website (http://www.mlst.net). The colored ring denotes known or proposed species for each ST (yellow, S. aureus; gray, S. argenteus).
Clinical manifestations and outcomes for patients infected with MSSA or S. argenteus
| Clinical parameter | Data for patients with | ||
|---|---|---|---|
| MSSA | |||
| Total cases | 199 | 10 | |
| Age (yr) | 38 (14–59, 1–84) | 56.5 (41–66, 11–73) | 0.04 |
| Sex (male) | 118 (59) | 7 (70) | 0.74 |
| Blood culture-positive isolates | 56 (28) | 3 (30) | >0.99 |
| Place of acquisition | |||
| Community acquired | 172 (86) | 8 (80) | 0.63 |
| Health care associated | 27 (14) | 2 (20) | |
| Underlying medical condition | 65 (33) | 7 (70) | 0.03 |
| Cardiac disease | 12 (6) | 1 (10) | 0.48 |
| Diabetes mellitus | 29 (15) | 6 (60) | 0.002 |
| Renal disease | 15 (8) | 6 (60) | <0.001 |
| Immunosuppression | 25 (13) | 2 (20) | 0.62 |
| Lung disease | 9 (5) | 1 (10) | 0.39 |
| Pattern of disease | |||
| Identified site, bacteremia only | 17 (9) | 2 (20) | 0.19 |
| 1 identified site | 155 (78) | 6 (60) | |
| >1 identified site | 27 (13) | 2 (20) | |
| Other identifiable sites of infection | |||
| Superficial abscess | 81 (41) | 4 (40) | 0.15 |
| Deep abscess | 45 (23) | 0 | |
| Other skin and soft tissue infections | 21 (11) | 4 (40) | |
| Bone and joint infections | 24 (12) | 2 (20) | |
| Prosthetic material infection | 13 (7) | 0 | |
| Respiratory infection | 14 (7) | 0 | |
| Endocarditis | 6 (3) | 0 | |
| Other infection | 7 (4) | 0 | |
| Outcome | |||
| Cured | 150 (75) | 7 (70) | 0.58 |
| Treatment failure | 11 (6) | 1 (10) | |
| Death due to | 26 (13) | 1 (10) | |
| Death due to other causes | 12 (6) | 1 (10) | |
Data shown are number (%) or median (interquartile range, range).
P values were estimated using Fisher's exact test. Values for age were estimated using the Mann-Whitney test.
Health care-associated infections included nosocomial and nonnosocomial health care-associated infections (12).
Past medical history of any underlying chronic medical conditions reported by the patients and/or relatives or recorded in the medical notes.
“Cardiac disease” comprised congenital heart disease, valvular heart disease (including rheumatic heart disease), ischemic disease, or arrhythmias (including heart block requiring pacemaker).
“Renal disease” included end-stage renal failure with long-term dialysis and chronic renal failure (not on dialysis) due to diabetes mellitus, systematic lupus erythematous, multiple myeloma, glomerulonephritis, or an unknown etiology.
Immunosuppression included that from HIV, chemotherapy, untreated leukemia, radiotherapy, or immunosuppressive medications, including >30 mg/day of prednisolone for >1 week.
“Lung disease” comprised previously treated tuberculosis, previous empyema, lung cancer, long-term tracheostomy, chronic obstructive pulmonary disease, or asthma.